Download Immunization Competencies Education Program Module 1

Program Name:
Immunization Competencies Education Program
Module 1 - The Immune System and Vaccines
Adapted by:
Faculty:
Michael Boivin, B. Pharm.
Susan Bowles, BSc Phm, PharmD, MSc
Capital District Health Authority and Dalhousie University, Geriatric
Ambulatory Care
Danielle Grenier, MD
Canadian Paediatric Society
Alex Henteleff, BN, MEd
Consultant Public Health
Expert video commentary was kindly provided by:
Upton Allen, MD, FRCPC, MBBS, FAAP
Maryanne Crockett, MD, MPH
Andrea Derban, BScN
Simon Dobson, MD
Joanne Embree, MD
Ian Gemmill, MD, CCFP, FCFP, FRCP(C)
Caroline Quach, MD, FRCPC, M. Sc.
CCCEP:
This continuing education lesson is designed primarily for
community pharmacists and has been accredited by the Canadian
Council on Continuing Education in Pharmacy (CCCEP) for 1 CEUs.
CCCEP File Number: 1066-2010-092-I-P
This online CME event is an Accredited Group Learning Activity
(Section 1) as defined by the Maintenance of Certification program
of the Royal College of Physicians and Surgeons of Canada. This
program is recognized as 1 hour(s) of Continuing Professional
Development.
Family physicians may claim one (1) credit per hour of participation
under Mainpro-M2.
Course Expiration Date:
June 15, 2013
Sponsor:
This module is developed in collaboration with the Canadian Paediatric
Society, the Public Health Agency of Canada and Health Canada.
© Copyright 2011
1
Competency: Explains how vaccines work using a basic knowledge of the immune system
Learning Objectives
Upon successful completion of this section the health professional will be able to perform
the following:
1.
2.
3.
4.
5.
Compare and contrast innate and adaptive immunity.
Differentiate between the primary and memory immune response to a vaccine.
Differentiate between passive and active immunity.
Explain why some vaccines induce a memory response while others do not.
Name some host- and vaccine-related factors that affect the immune response to
vaccines.
6. Explain how the immunization schedule accommodates factors that affect the immune
response to vaccines.
7. Respond to the concern that giving too many vaccines will overload the immune system.
8. Discuss the pros and cons of immunity gained through immunization as opposed to
wild-type infection.
Test Your Current Knowledge
Based on your current knowledge, please indicate if you feel the statement listed is true or false.
1. With a live attenuated vaccine the pathogen actually replicates in the patient’s body.
a.
True
b.
False
2. The innate immune system is crucial for inducing long-term immunity.
a.
True
b.
False
3. The adaptive immune response involves the activation of both the T cells and the B
cells.
a.
True
b.
False
4. Subunit vaccines are safe to administer in patients who are immunocompromised.
a.
True
b.
False
© Copyright 2011
2
5. Adjuvants are added to subunit vaccines to enhance and prolong immune response.
a.
True
b.
False
6. Closely spaced primary vaccine doses may be administered when a rapid induction of
protection is desirable. This raises less persisting responses than when the same
number of vaccine doses are given at longer intervals.
a.
True
b.
False
7. The response to subunit vaccines is comparable to “wild” type infection.
a.
True
b.
False
8. Multiple immunizations can be administered at a single time at different sites as the
antigenic response will occur at different regional lymph nodes.
a.
True
b.
False
9. Memory B cells are crucial for long-term immunity as they consistently produce
antibodies to maintain this memory.
a.
True
b.
False
10. Adjuvants are not used in a large amount of vaccines as they dramatically increase the
risk of adverse effects.
a.
True
b.
False
Immunology Basics
Immunology is a complicated subject and a detailed review is beyond the scope of this lesson.
For professionals administering immunizations, knowledge of the basic function of the immune
system is useful in order to understand the physiological effect of vaccines once injected and the
basis of recommendations for their use.1
Immunity is the ability of the human body to protect itself from infectious diseases. Some of the
key concepts are innate immunity, passive immunity, and adaptive (active) immunity.
Innate Immunity
Innate immunity refers to nonspecific defence mechanism that comes into play immediately or
within hours of an antigen appearing in the body. It is activated by chemical properties of the
© Copyright 2011
3
antigen. The mechanisms of the innate immune system include anatomical barriers, secretory
molecules and cellular components. These defence mechanisms are common amongst all
normal individuals as they are born with them. Innate immunity comprises the inborn immune
mechanisms that do not depend upon previous exposure to an antigen.2 Table 1 lists some of
the key components of the innate immune system.
One major component of the innate immune system is the antigen non-specific disease
mechanisms that a host uses immediately or within several hours after exposure to almost any
microbe. Unlike adaptive immunity it does not recognize every possible antigen. It is designed to
recognize molecules shared by groups of related microbes. These molecules include a wide
number of highly conserved microbial structures and are called pathogen-associated molecular
patterns (PAMP). Most of the body’s defence cells have pattern-recognition receptors (PRR) for
these PAMP and so there is an immediate response against the invading microorganism. The
steps involved in the innate system are listed below:
1. A foreign substance such as a toxin or microbe breaches the physical barriers of the
innate immune system.
2. Pathogen-associated molecular patterns (PAMP) are recognized by pattern-recognition
receptors (PRR).
3. PRR are on a large variety of defence cells including phagocytic cells (neutrophils,
monocytes, macrophages), cells that release inflammatory mediators (basophils, mast
cells and eosinphils), and natural killer cells (NK).
4. This binding promotes the release of inflammatory cytokines that are crucial to initiating
the innate and adaptive immune system. Cytokines trigger innate immune defences
such as inflammation, fever and phagocytosis in order to provide an immediate
response against the invading organism They also stimulate the complementary
immune response which promotes lysis of cells and phagocytosis of the infecting
pathogen.
5. On the dendritic cells of the defence system there is a certain type of PRR called toll-like
receptors that are responsible for the activation of the adaptive immune system.
Key points regarding the innate immune system:
•
•
•
•
•
It is a fast-acting and immediate response to a foreign pathogen.
First line of defence.
It stimulates the adaptive immune response.
Innate immune response does not improve with repeated exposure to a given infection.
It has no memory of the invading pathogen.
Table 1- Components of the Innate Immune System3,4
Component
© Copyright 2011
Notes
4
Mechanical
barriers
•
Physicochemical •
barriers
Antibacterial
substances
•
•
•
•
•
Mechanical Factors •
Biological Factors •
The integrity of the epidermis and mucosal membranes that are impermeable to most
infectious agents
The acidity of the stomach fluid
Fatty acids in sweat inhibit the growth of bacteria.
Lysozyme and phospholipase found in tears, saliva and nasal secretions can breakdown
the cell wall of bacteria and destabilize bacterial membranes.
The low pH of sweat and gastric secretions prevents growth of bacteria.
Defensins (low molecular weight proteins) found in the lung and gastrointestinal tract
have antimicrobial activity.
Surfactants in the lung act as opsonins (substances that promote phagocytosis of particles
by phagocytic cells).
Normal intestinal transit and normal flow of bronchial secretions and urine eliminate
infectious agents from the respective systems.
The normal flora of the skin and in the gastrointestinal tract can prevent the colonization
of pathogenic bacteria by secreting toxic substances or by competing with pathogenic
bacteria for nutrients or attachment to cell surfaces.
Passive Immunity
Passive immunity is immediate protection provided through the transfer of antibodies from
immune individuals.1 This is most commonly passed through the placenta from mother to
neonate and less commonly through the transfusion of blood or blood products including
immunoglobulin.1 The cross-placental transfer of antibodies from mother to child is more
effective against some infections (e.g. tetanus and measles) than for others (e.g. polio and
whooping cough).1
With passive immunity the protection is temporary and commonly for only a few weeks or
months.1
Adaptive (Acquired) Immunity
Adaptive or acquired immunity is the specific protective mechanism as a consequence of
infection with a disease causing agent or by deliberate immunization against that disease with
vaccination.2
The adaptive immunity is quite different from the innate system as it:
© Copyright 2011
5
•
•
•
Is designed to remove a specific antigen.
Takes several days to become protective.
Immunity is long-term and can even persist for a lifetime.
The adaptive immune response involves two systems including humoral immunity and cellmediated immunity.
It starts with antigen exposure
An antigen is any substance (usually a protein or polysaccharide on the surfaces of viruses and
cells) and is able to induce an immune response. These compounds are recognized by the
immune system as foreign to the body.
If the antigen is sufficient to elicit a response, they will activate the innate immune system
(listed above) and immature dendritic cells that patrol throughout the body. When the toll-like
receptors of the dendritic cells are exposed to an antigen they undergo brisk maturation,
modulate specific surface receptors and migrate towards secondary lymph nodes, where the
induction of T and B cell responses occur (cell mediated and humoral immunity).5
Cell-mediated immunity
The mature dendritic cells (antigen presenting cells) provide antigen-specific and costimulation
signals to T cells. These “danger signals” are required for the naïve T cells to mature into
immune effector T4 or T8 cells.5 Effector lymphocytes are immune cells that encounter an
antigen, proliferate and mature into a form capable of actively carrying out immune defences.
The activated effector T4 cells have a variety of functions for the immune response. T-helper
cells regulate the immune response with the cytokines they produce. The main functions of the
effector T4 cells include:
•
•
Stimulating the immune response of other cells such as the B-cells to produce
antibodies (discussed later).
Differentiating into T helper 1 (Th1), T helper 2 (Th2) and T helper 17 (Th17) cells.
o Th1 cells produce cytokines that promote cell-mediated immunity especially
against intracellular microbes (such as viruses) by activating macrophages and
cytotoxic T-lymphocytes. They also promote antibody production.
o Th2 cells produce cytokines that promote responses to helminths (parasitic
worms) and allergens. They also promote the production of antibodies that
neutralize microbes and toxins.
o Th17 cells promote inflammation and attracts neutrophils. It may help to
remove extracellular organisms from the body.
The activated effector T8 cells are also known as the cytotoxic T lymphocytes. These cells are
one of the body's major defences against viruses, intracellular bacteria, and cancers. They help
to destroy infected cells and tumour cells. They recognize infected cells that have the specific
antigen they were presented with by the mature dendritic cells and destroy these cells.
Humoral immunity
© Copyright 2011
6
Another key component of our immune system is humoral immunity. This process is initiated
with B-lymphocytes. Naïve B lymophocytes are produced in the bone marrow and circulate until
they encounter a protein antigen to which their specific surface IgM receptor binds.5 Antigen
binding initiates the B cell activation and drives antigen-specific B cells towards the outer T cell
zones of the secondary lymph node tissues.5 At this location, antigen-specific B cells are exposed
to recently (<24 h) activated dendritic cells and T cells and they provide B cell activating signals.
The interaction with the T cells helps rapidly drive B cell differentiation into antibody secreting
plasma cells.5
Antibodies are proteins found in the blood that are produced in response to foreign substances
(i.e. bacteria or viruses invading the body). Antibodies protect the body from disease by binding
to these organisms and facilitate their destruction by a variety of mechanisms.
Memory cells
When the B-cells are differentiating into plasma cells that secrete antibodies a portion of these
cells are converted to memory cells. These memory cells do NOT produce antibodies and do not
protect the body like plasma cells. The pool of B-memory cells migrate to lymph nodes, to
mucosal tissue, and circulate in the blood waiting to encounter the original antigen if it enters
the body again (i.e secondary exposure). If they are re-exposed to the specific antigen, they
rapidly convert to antibody secreting plasma cells. Some unique characteristics of the memory B
cells are:5
•
•
•
•
•
•
•
They are only generated in the initial cell mediated immune response described above.
They are resting cells that do not produce antibodies.
Memory cells undergo affinity maturation during several (4-6) months.
They rapidly (within days) differentiate into antibody secreting plasma cells upon reexposure to the antigen. This leads to a rapid response if the body is re-exposed to the
pathogen, sometimes the infection is so mild the patient is unaware they are even
infected.
The antibodies they produce have a higher affinity than those produced by the primary
plasma cells.
Upon re-exposure to the antigen, they can convert to plasma cells with lower amounts
of antigen and without the help of T-helper cells.
They are believed to be responsible for long-term or even lifelong immunity.
© Copyright 2011
7
© Copyright 2011
8
Vaccines and Immune Response
The primary role of vaccines is to induce
active (adaptive) immunity and provide
immunological memory.1 This is best
achieved through immunization programs
capable of activating the adaptive (active)
immune system as it induces long-term
protection.5
Clinical Tip:
Multiple immunizations can be
administered at a single time at
different sites as the antigenic response
will occur at different regional lymph
nodes.
Long-term immunity with vaccination is
only possible through the maintenance of
antigen-specific immune memory cells that
may be sufficiently efficient and can rapidly
reactivate into immune effector cells when
exposed to the natural disease.5
Vaccines can be made from inactivated (killed) or attenuated live organisms, secreted products
(e.g. tetanus toxoids), recombinant components or the constituents of cell walls. Some vaccines
contain inactivated bacteria or viruses. Other vaccines contain only the antigens that are
important for protection.
The ability of a vaccine to exhibit its response in the body is determined by the type of vaccine
administered. These include live attenuated vaccines, inactivated vaccines and subunit vaccines
Live Attenuated Vaccines
This type of vaccines contains whole, living bacteria or viruses that induce their immunity by
actively replicating within the host.6 Live vaccines are attenuated which means the vaccine
strains are weakened so that the infection is usually not apparent or very mild in contrast to the
natural or “wild” infection.
The organism in the vaccine replicate within the person and it mimics a natural infection.
Following injection microorganism particles rapidly disseminate throughout the vascular
network and reach their target tissues.5 This replication and dissemination throughout the body
stimulates dendritic cells at multiple sites in the body and causes their migration to multiple
lymph nodes.5 This leads to a multiple foci T and B cell activation.5 With this large immunogenic
response most recipients produce immunity with one dose.7
Live attenuated vaccines are contraindicated in patients with immunodeficiencies as these
vaccines can lead to uncontrolled replication of the vaccine virus. This includes patients such as
those with long-term immunosuppressive therapy for organ transplantation [high dose steroid
therapy (≥ 2mg/kg/day, or ≥ 20 mg per day for ≥ 14 days], chemotherapy, or
immunosuppressive agents such as cyclosporine) and in inflammatory conditions (i.e. inflixmab
for inflammatory bowel disease or arthritis).6 Patients who are immunocompromised have no
absolute contraindication for live attenuated vaccines early in the course of their illness, but as
their condition progresses the risk of using live vaccines also increases.6
© Copyright 2011
9
Inactivated Vaccines
The vaccine contains killed bacteria or virus therefore there is no risk of uncontrolled replication
of the virus in immunocompromised persons.6 While these vaccines can induce broad immunity
when multiple antigens are present, the immune response might be blunted in persons who are
not fully immunocompetent.6 With the absence of microbial replication seen with live
attenuated vaccines, vaccine induced activation remains more limited both in time and space.5
Non-live vaccines activate innate response at their sites of injection and the site and route of
administration is more important than with live vaccines.5 Most of these vaccines should be
injected in a well vascularised muscle as they contain a large number of patrolling dendritic cells
capable of interacting with the vaccine.5 Subcutaneous injections are generally less effective due
to the limited number of dendritic cells in the adipose tissue.5 Adjuvants (discussed later) are
commonly added to these formulations to increase immune response.
Inactivated vaccines almost always require multiple doses. The first dose does not produce
protective immunity, but “primes” the immune system.7 A protective immune response
develops after the second or third dose.7 Unlike live vaccines, the level of response is not
comparable to a “wild” infection and the protection provided by the vaccine will diminish over
time.7 For this reason some inactivated vaccines may require periodic supplemental doses to
increase or “boost” antibody levels.7
Subunit Vaccines
Subunit vaccines contain purified products that usually come from the bacteria or virus that
causes the natural infection but may also be synthesized using recombinant technology.6 The
end products include proteins, polysaccharides and protein-polysaccharide conjugates.6 These
vaccines have excellent safety profiles and facilitate the preparation of a variety of combination
products with multiple antigens to different infections.7 The disadvantage of these products is
they do not elicit a high immune response compared to live vaccines.6
The adaptive immune response to a subunit vaccine varies according to whether the vaccine
antigen is a protein or a polysaccharide. Subunit vaccines based on protein antigens or
conjugated polysaccharide-protein antigens are T-dependent vaccines whereas polysaccharides
generate a T-independent response.8
Of special note in this group are the polysaccharide-only antigens. The polysaccharides to do not
elicit a large local immune response and they reach the lymph nodes not through activated
dendritic cell transport but through the blood. They reach the marginal zones of the lymph
nodes and bind to B-cells that undergo maturation to plasma cells independent of the T helper
cells. This leads to a significantly poorer response and does not stimulate the production of
memory cells. This leads to a rapid decrease in antibody protection over a short period of time.
Revaccination with certain polysaccharide immunizations may even induce a lower antibody
response than the first immunization, a phenomenon known as vaccine hyporesponsiveness.5
The Differences Between Natural Infection and Vaccine Immunity
There are two methods for achieving immunity to a microbe: natural infection and by
© Copyright 2011
10
vaccination.9
Natural infection occurs when a patient is exposed to someone in the community with the
disease, contracts the disease, and develops symptoms.9 The patient will contract the disease
and develop symptoms. This infection can also lead to complications associated with the
disease. Usually natural infection leads to the induction of memory and the patient is protected
long-term.9
Vaccines can be used to stimulate the immune system to develop antibodies to the bacteria or
virus. Unlike natural immunity it will normally require multiple injections to provide the same
level of protection (exception is live attenuated vaccines). The response to some vaccines is not
as long as natural infection and will require booster shots to provide long-term immunization.
Both the natural infection and vaccine immunity will protect against infection from the bacteria
or virus. The difference with vaccinations is that the person does not have to endure the illness
and its potentially life-threatening complications to induce immunity.9
Adjuvants
Adjuvants are commonly added to subunit vaccines and many inactivated vaccines to
enhance the immune response. The incorporation of adjuvants into vaccine
formulations is aimed at enhancing, accelerating and prolonging the specific immune
response towards the desired response to vaccine antigens.10 Advantages of adjuvants
include enhancement of the immunogenicity of antigens, modification of the nature of
the immune response, reduction of the antigen amount needed for a successful
immunisation, the reduction of the frequency of booster immunisations needed and an
improved immune response in elderly and immunocompromised patients.10
• The only adjuvants currently used in routine immunization are the aluminum
salts (aluminum hydroxide, aluminum phosphate or potassium aluminum
sulphate).6 None of the currently available adjuvants trigger the degree of innate
immune response that is elicited by live vaccines whose immune potency far
exceed that of non-live vaccines.5
• The pH1N1 vaccine used an adjuvant containg DL-a-tocopherol, squalene and
polysorbate 80. More information of this adjuvant is available at:
http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimordersarretesurgence/prodinfo-vaccin-eng.php
Adjuvants are believed to increase the danger signals and trigger a sufficient activation
of the innate immune system.5 These adjuvants:
Are delivery systems that prolong the antigen deposit at the site of injection,
recruiting more dendritic cells into the reaction.
• Are immune modulators that provide additional differentiation and activation
signals to monocytes and dendritic cells.5
6
• Have been shown to be safe over decades of use.
Rarely adjuvants cause injection site reactions including subcutaneous nodules,
granulomatous inflammation (growth or lump) or contact hypersensitivity.6
•
© Copyright 2011
11
Determinants of Vaccine Response
There are a number of determinants that modulate the intensity of vaccine antibody response.
These factors are listed in table 2.
Table 2 – Determinants of Vaccine Antibody Response
Vaccine Type
•
•
•
5
The nature of the vaccine directly influences the activation of the innate immune
system and vaccine response.
Live attenuated vaccines have a significantly higher antibody response and
persistence in the patient.
Polysaccharide only antigens have limited immune response and no memory.
Vaccine
Adjuvants and
Carrier Proteins
•
Optimal Antigen
Dose
•
Higher doses of non-live antigens (up to a certain threshold) elicit higher primary
antibody responses.
Interval between
priming doses
•
Closely spaced (1–2 weeks) primary vaccine doses may be administered when a
rapid induction of protection is desirable, e.g., prior to travel. However, this raises less
persistent responses than when the same number of vaccine doses are given at longer
(1–2 months) intervals.
A minimal interval of 4 weeks between primary doses allows development of
successive waves of antigen specific primary responses without interference.
•
•
Interval before
boosting
•
•
•
Age
© Copyright 2011
•
•
•
The addition of adjuvants enhances immune response and extends the duration of
B and T cell activation.
Conjugating a polysaccharide with a carrier protein leads to a significantly higher
immune response.
The maturing process of the memory cells takes several months.
A classical prime then boost immunization schedule allows 4-6 months to elapse
between priming and boosting doses.
This has lead to the development of the generic 0,1,6 month schedule for many
vaccines.
Extremes of age of life have shorter antibody persistence.
Younger infants have immune system immaturity.
Older patients have a gradual deterioration of their immune system
(immunosenescence).
12
Certain Medical
conditions
•
Patients who are immunocompromised are less likely to mount as good an
antibody response as immunocompetent patients
Responding to the Concerns of Parents – Patient Counselling Tip
Immunization Myth – “Administering vaccines weakens and overloads the child’s immune system”
1
From birth and in early infancy and childhood, humans are exposed to countless numbers of foreign
antigens and infectious agents in the everyday environment. Responding to these stimuli helps the
immune system to develop and mature. Compared with exposure in the natural environment,
vaccines provide specific stimulation to a very small number of antigens. Responding to these
specific antigens uses only a tiny proportion of the capacity of an infant’s immune system. If an
infant’s immune system could be exhausted by multiple vaccines, one would expect vaccinated
children to be at a higher risk of serious infections. Studies to investigate whether vaccines increase
susceptibility to serious infections have shown no evidence of such an effect, with infection rates
generally being lower in vaccinated children.
Vaccine Immunology Summary
Vaccine immunology is a complex subject. The information in this section only provides a quick
and simplified overview of the factors responsible for appropriate vaccine response. A basic
understanding of vaccine immunology is crucial to appreciate the interaction of these products
with the immune system of patients.
Visit www.AdvancingPractice.com to watch Dr. Simon Dobson summarize the primary and
secondary immune response to a vaccine.
Visit www.AdvancingPractice.com to watch Dr. Simon Dobson as he discusses the induction of
memory cells and the role of booster immunizations using human papillomavirus as an example.
Key Learning Points
1. The innate immune system is a non-antigen specific defence mechanism. It is comprised
of physical barriers as well as a system to identify common pathogen-associated
molecular patterns (PAMP) by pattern recognition receptors (PRR)
2. The innate immune system is fast-acting, stimulates the adaptive immune response,
does not improve with repeated exposure and has no memory
3. Passive immunity is immediate protection provided through the transfer of antibodies
from immune individuals. This is most common in pregnancy but can also occur through
the transfusion of blood or blood products containing immunoglobulins. This protection
is temporary
4. The adaptive immune system is an antigen specific defence mechanism. It normally
takes several days to become protective but the immunity is long-term and can even
persist a lifetime
© Copyright 2011
13
5. Steps to a cell-mediated immune response include:
o Dendritic cells exposed to the antigen at the site of infection mature and
modulate surface receptors and migrate towards the secondary lymph nodes
o These mature dendritic cells present the antigen and help to activate naïve Tcells
o Effector T4 cells are helper cells that facilitate the humoral immune response
o Effector T8 cells are cytotoxic cells that help to destroy infected cells
6. The humoral system is responsible for antibody production. Steps of humoral response
include:
o An antigen binds to a naïve B-lymphocyte, activates the B-cell and drives the
specific B-cell towards the outer T-cell zones of the lymph nodes
o Activated effector T4 cells cause the conversion of activated B-cells into
antibody secreting plasma cells
o These antibodies protect the body from disease by binding to organisms and
facilitating their destruction by a variety of mechanisms
7. Most of the cells involved in the primary immune response die within a matter of weeks.
If the immune response was sufficient a small number of B-cells are converted to
memory cells. These cells:
o Do not produce antibodies
o Rapidly mature to antibody secreting cells with re-exposure to the antigen
(secondary exposure)
o Are believed to be responsible for long-term immunity
8. The goal of vaccines is to induce adaptive immunity and provide immunological
memory. This will help to protect the patient in the future if they are exposed to the
wild disease
9. The key vaccine types are:
o Live attenuated vaccines – Containing weakened virus or bacteria that replicate
in the body
o Inactivated vaccines – Containing killed a bacteria or virus
o Subunit vaccine – Containing purified products that usually come from the
bacteria or virus that causes the natural infection but may also be synthesized
using recombinant technology. The end products include proteins,
polysaccharides and protein-polysaccharide conjugates
10. Several factors can influence antibody response. These include:
o Vaccine type
o Adjuvants
o Antigen dose
o Interval between priming dose
o Interval before boosting
o Age of the patient
o Certain medical conditions
© Copyright 2011
14
Discussion Forum
1. Vaccine immunology is a complex topic and can be difficult to explain to patients. Are there
any strategies or education sources that you have found helpful when discussing this topic with
your patients?
2. The antivaccine movement suggests that immunizations will overload or “use up” a child’s
immune system. Do you have any counselling tips that you can share that helped when
educating your patient on these myths?
3. Please describe two examples of information/key learning you acquired through this program
that are immediately applicable to your practice and patient counselling
4. Are there any additional topics on vaccine immunology that you feel would be helpful?
Post Test
1. Which of the following is NOT a component of the innate immune response
a. It is a non-specific immune response
b. It is an inborn immune mechanisms that do not depend upon previous exposure
to an antigen
c. It recognizes every possible antigen
d. It is the first line of defence
2. Which of the following are the initial steps of cell-mediated immunity
a. Antigen entry, exposed to toll-like receptors on dendritic cells, dendritic cell
mature and migrate to regional lymph nodes
b. Antigen entry, activation of B-cells, this matures dendritic cells and stimulates Tcells to produce antibodies
c. Antigen entry, activation of T-helper cells and this stimulates antibody secretion
by the dendritic cells
d. Antigen entry, T4 and T8 cells mature and start to release antibodies
3. Which of the following is true regarding memory B-cells?
a. They are part of the innate immune response
b. They secrete large amounts of antibodies to keep the levels high to prevent
reinfection
c. Upon re-exposure to the antigen, they can convert to plasma cells with lower
amounts of antigen
d. They can produce a large amount of antibodies if activated but the antibodies
have a lower affinity for the antigen
4. Which of the following statements regarding adjuvants is TRUE?
© Copyright 2011
15
a. Most of the adverse effects with adjuvants can be minimized if they are injected
subcutaneously
b. Adjuvants increase the danger signals and trigger a sufficient activation of the
innate immune system
c. Adjuvants are normally added to all vaccine types to increase immune response
d. Adding an adjuvant to a subunit vaccine triggers the innate immune response to
the same degree as a live vacccine
5. Which of the following factors determines the vaccine response?
a. Conjugation of with a carrier protein
b. Interval between priming doses
c. Age
d. All of the above
Your colleague has called you to ask your opinion regarding one of his patients. He
explains the patient is immunocompromised but through discussions is in need of some
immunizations. He knows that you have a keen interest in immunization and he
wanted your opinion.
6. Which type of vaccine should be avoided in immunocompromised patients?
a. Live attenuated vaccine
b. Subunit vaccine
c. Inactivated vaccine
d. Any vaccine with an adjuvant
7. If you were to give an inactivated vaccine to an immunocompromised patient which of
the following is a concern?
a. Potential for growth of the virus or bacteria in the immunocompromised patient
b. Site and route of administration is important to ensure full response from the
dendritic cells
c. Blunted immune response due to being immunecompromised
d. Both (b) and (c)
References
1. Salisbury D, Ramsay M, Noakes K. Immunisation against infectious disease. London: TSO;
2006.
2. Cruse J, Lewis R, Wang H. Immunology Guidebook. London: Elsevier; 2004.
3. Virella G. Medical Immunology. New York: Marcel Dekker; 2005.
4. Innate or non-specific immunity. Available at:
http://pathmicro.med.sc.edu/ghaffar/innate.htm [Accessed February 28, 2010].
5. Plotkin S, Orenstein W, Offit P. Vaccines. London: Elsevier; 2008.
6. National Advisory Committee on Immunization. Canadian Immunization Guide. Seventh.
Ottawa, Ontario: Public Health Agency of Canada; 2006.
© Copyright 2011
16
7. NCIRD. Pubs/PinkBook/Chapters. Available at:
http://www.cdc.gov/vaccines/pubs/pinkbook/pink-chapters.htm [Accessed February
28, 2010].
8. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup
Med (Lond). 2007;57(8):552-556.
9. Gold R. Your Child's Best Shot. 3rd ed. Ottawa, Ontario: Canadian Paediatric Society;
2006.
10. Committee for Medicinal Products for Human Use (CHMP). GUIDELINE ON ADJUVANTS
IN VACCINES FOR HUMAN USE. London: The European Medicines Agency Evaluation of
Medicines for Human Use; 2005.
© Copyright 2011
17